Why choose the Champions AML In Vivo Screen?
28 Clinically Relevant Models
Living & diverse bank of primary patient AML models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' elite AML In Vivo Screen, an advanced platform showcasing 28 primary Acute Myeloid Leukemia (AML) models, each reflecting diverse and complex AML subtypes.
-
Includes models pretreated with advanced therapies like gilteritinib, Mylotarg, and CSF1R inhibitors, as well as those with del(7q)
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and kinase activity)
-
Terminal flow cytometry analysis on peripheral blood and bone marrow
-
AML Engraftment Assessement using Champions' Standard systemic AML In Vivo engraftment panel: CD3, CD33, CD34,CD38, mCD45, hCD45, CD117, CD123, Viability Dye
-
Plasma-based Luminex available
Champions' Systemic AML In Vivo Screen
Champions' Industry-leading Clinical Annotation & Multi-omic Characterization
AML In Vivo Screen: Terminal Bone Marrow Flow Cytometry Results